![](https://blogger.googleusercontent.com/img/b/R29vZ2xl/AVvXsEhOMi7Yrn9UWso0JHXP2e8yEcbVYxqUmy7MTBx-n5BYxql7zJzgnDxeba_lDcf0uebVBbUBfivCc9AtmYpsR3Uu44PP0EcOBBEfeNQZNxegQ53yscq07zRJgJApnwrLrGdcB7GU58CZ1Prv/s320/img_fdagov_logo_type.gif)
Guidance for Industry: “Lookback” for Hepatitis C Virus (HCV): Product Quarantine, Consignee Notification, Further Testing, Product Disposition, and Notification of Transfusion Recipients Based on Donor Test Results Indicating Infection with HCV
PDF Printable Version [PDF 245KB]
http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/UCM238488.pdf
Additional copies of this guidance are available from Office of Communication, Outreach and Development (OCOD) (HFM-40), 1401 Rockville Pike, Suite 200N, Rockville, MD 20852-1448, or by calling 1-800-835-4709 or 301-827-1800, or email ocod@fda.hhs.gov, or from the Internet at
http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm.
For questions on the content of this guidance, contact OCOD at the phone numbers listed above.
Biologics Guidances > Guidance for Industry: “Lookback” for Hepatitis C Virus (HCV): Product Quarantine, Consignee Notification, Further Testing, Product Disposition, and Notification of Transfusion Recipients Based on Donor Test Results Indicating Infection with HCV
No hay comentarios:
Publicar un comentario